{"preliminary_commentary":{"by_channel":{"bluesky_thread":3,"x_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"MonumenTAL-6","nct_id":"NCT06208150","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=monumental-6-nct06208150. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MonumenTAL-6","arms":[{"description":"Participants will receive talquetamab as subcutaneous (SC) injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug.","label":"Arm A: Talquetamab + Pomalidomide (Tal-P)","type":"EXPERIMENTAL"},{"description":"Participants will receive teclistamab in combination with talquetamab both as SC injection; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug.","label":"Arm B: Talquetamab + Teclistamab (Tal-Tec)","type":"EXPERIMENTAL"},{"description":"Participants will either receive elotuzumab intravenous (IV) injection in combination with pomalidomide and dexamethasone orally; or pomalidamide orally in combination with bortezomib SC injection and dexamethasone orally as per investigator choice. Dexamethasone will be administered as a pretreatment medication.","label":"Arm C: Elotuzumab+ Pomalidomide+Dexamethasone (EPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":838,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Talquetamab","otherNames":["JNJ-64407564","Talvey"],"type":"DRUG"},{"name":"Pomalidomide","otherNames":["Pomalyst","Imnovid"],"type":"DRUG"},{"name":"Teclistamab","otherNames":["JNJ-64007957","Tecvayli"],"type":"DRUG"},{"name":"Elotuzumab","otherNames":["Empliciti"],"type":"DRUG"},{"name":"Dexamethasone","otherNames":[],"type":"DRUG"},{"name":"Bortezomib","otherNames":["Velcade"],"type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Janssen Research & Development, LLC","official_title":"64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-04-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"Up to 3 years 5 months"}],"references":[],"start_date":{"date":"2024-01-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide","url":"https://clinicaltrials.gov/study/NCT06208150"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/monumental-6-nct06208150"}